MétaCan
Menu
← Back to cohort
Record W2149951063 · doi:10.1200/jco.2004.99.042

A Recent Illustration of Some Essentials of Circadian Chronotherapy Study Design

2004· letter· en· W2149951063 on OpenAlexaff
William J.M. Hrushesky, Patricia A. Wood, Françis Lévi, Reinhard von Roemeling, Georg A. Bjarnason, Christian Focan, Klaus Meier, Germaine Cornélissen, Franz Halberg

Bibliographic record

VenueJournal of Clinical Oncology · 2004
Typeletter
Languageen
FieldMedicine
TopicOvarian cancer diagnosis and treatment
Canadian institutionsUniversity of TorontoSunnybrook Health Science Centre
Fundersnot available
KeywordsChronotherapy (sleep phase)MedicineCircadian rhythmIntensive care medicineInternal medicine

Abstract

fetched live from OpenAlex

TO THE EDITOR: In 1985, a comparison of the circadian timing of doxorubicin 60 mg/m 2 and cisplatin 60 mg/m 2 given every 28 days to patients with large-volume stage III and stage IV ovarian cancer was published. 1 This comparison of morning doxorubicin and evening cisplatin with evening doxorubicin and morning cisplatin was based on studies in a rat model that predicted that morning doxorubicin followed by evening cisplatin would be less toxic and more effective. 2 The two circadian schedules, compared with one another, kept the order of the drugs constant and the interval between them constant, because other studies had shown that the sequence of and intervals between cytotoxic drugs are also temporal sources of potential relevance to both cytotoxic drug toxicity and efficacy. Patients treated with the morning doxorubicin and evening cisplatin schedule had fewer infections and fewer bleeding episodes; required fewer RBC transfusions; had less nausea, fewer vomiting episodes, and less emesis; had less severe renal damage; and experienced less frequent and less severe peripheral neuropathy. The WBC and platelet counts in patients treated with this schedule recovered by day 21, while the opposite circadian schedule resulted in cumulative marrow toxicity. This resulted in diminished dose intensity. At the same time, the patients treated with the least toxic schedule had a four-fold greater 5-year rate of survival. 3 These findings were confirmed with related drugs in European ovarian cancer patients. 4 A presentation of these data to the members of the Gynecologic Oncology Group (GOG) followed. The ovarian cancer committee had other priorities, but the endometrial cancer committee expressed interest, even though no chronotherapeutic data were available for that cancer. A single-arm study of 6 AM doxorubicin, followed by cisplatin 12 hours later, resulted in an unexpectedly high objective response rate in advanced endometrial cancer. 5 GOG investigators subsequently wished to determine whether circadian doxorubicin and cisplatin timing was relevant to toxicity and outcome in patients with advanced endometrial cancer, and insisted that the control arm not specify drug timing. The ultimate study design specified the order of drugs for both regimens, doxorubicin first and cisplatin second, and required that in the control arm, both drugs be given together, while in the circadian arm, these agents were to be given 12 hours apart.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.204
metaresearch head score (Gemma)0.279
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesMetaresearch
DomainCandidate signal: Methods · Consensus signal: none
Study designCandidate signal: Theoretical or conceptual · Consensus signal: none
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.796
Threshold uncertainty score0.981

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.2040.279
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0010.002
Science and technology studies0.0020.004
Scholarly communication0.0030.002
Open science0.0050.002
Research integrity0.0080.012
Insufficient payload (model declined to judge)0.0050.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.250
GPT teacher head0.480
Teacher spread0.230 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.

Study designTheoretical or conceptual
DomainMethods
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations16
Published2004
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicOvarian cancer diagnosis and treatment→French-language works237,207→